Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Cleo Diagnostics Ltd

Cleo Diagnostics Ltd (COV.AX) Stock Overview

Explore Cleo Diagnostics Ltd’s financial performance, market position, analyst ratings, and future outlook.

COV.AX●ASX
HealthcareMedical - Devices
$0.27
$0.02(8.47%)
Australian Market opens in 53h 3m

Cleo Diagnostics Ltd (COV.AX)

Meyka AI Score

Z

Key Financials

Market Cap39.2M
P/E RatioN/A
EPS (TTM)$-0.04
ROEN/A
Fundamental Analysis

AI Price Forecasts

1 Month$0.25
3 Months$0.00
1 Year Target$0.00

COV.AX Stock Analysis & Investment Overview (ASX)

Our AI-powered analysis of Cleo Diagnostics Ltd (ASX: COV.AX) gives investors deep insight into how the stock performs on the ASX exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Cleo Diagnostics Ltd's ASX-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of COV.AX on the ASX shows an RSI of 38.87, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the ASX listing.

Key metrics behind Cleo Diagnostics Ltd's ASX-traded stock include a P/E ratio of N/A and a market capitalization of 39.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of COV.AX on the ASX.

Price Performance (ASX: COV.AX)

1-Day Change
1.82%
5-Day Change
-6.67%
1-Month Change
-20.00%
3-Month Change
-16.42%
6-Month Change
-51.72%
Year-to-Date (YTD) Change
-53.72%
1-Year Change
-29.11%
3-Year Change
40.00%
5-Year Change
33.33%
All-Time (Max) Change
33.33%

Contact Information

https://www.cleodx.com
NaN
480 Collins Street, Melbourne, VIC, 3000

Company Facts

IPO DateAug 22, 2023
CountryAU
Actively Trading

Frequently Asked Questions